BSD Medical gets FDA nod for new cancer treatment

Salt Lake-based BSD Medical Corp. said Tuesday it has received federal approval for a new operating system for the treatment of cancer patients.

The approval from the U.S. Food and Drug Administration is for a system using superficial and interstitial hyperthermia therapy.

BSD said the approval clears the way for the commercial introduction of four new systems to sales in the United States. The new systems have been six years in planning and development.

Superficial hyperthermia is used to non-invasively treat cancerous tumors within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer. Interstitial hyperthermia is used in treating prostate cancer, breast cancer, head and neck cancer and other cancers.